Upside in Madrigal Pharmaceuticals (MDGL) attributed to M&A chatter on Betaville with Eli Lilly (LLY) rumoured to be potential buyer - UNCONFIRMED
Context
The speculation around Madrigal Pharmaceuticals being a potential acquisition target for Eli Lilly suggests there could be strategic interests at play. While unconfirmed, this chatter could drive interest and volatility in MDGL's shares, as markets generally react positively to M&A rumors due to the premium typically associated with buyouts.
Trade the TapeGet this analysis live, the moment it breaksNewsquawk's real-time dashboard delivers market-moving headlines and instant context to your desk before the rest of the market reacts.
Open Dashboard#ELI LILLY & CO#LLY.US#RUMOUR#EQUITIES#US SESSION#PHARMACEUTICALS#PHARMACEUTICALS (GROUP)#PHARMACEUTICALS, BIOTECHNOLOGY & LIFE SCIENCES#S&P 500 INDEX#ELI LILLY AND CO#LLY#US EQUITIES